David Herrington to Treatment Outcome
This is a "connection" page, showing publications David Herrington has written about Treatment Outcome.
Connection Strength
0.325
-
Riley RF, Newby LK, Don CW, Roe MT, Holmes DN, Gandhi SK, Kutcher MA, Herrington DM. Diagnostic time course, treatment, and in-hospital outcomes for patients with ST-segment elevation myocardial infarction presenting with nondiagnostic initial electrocardiogram: a report from the American Heart Association Mission: Lifeline program. Am Heart J. 2013 Jan; 165(1):50-6.
Score: 0.061
-
Bray PF, Howard TD, Vittinghoff E, Sane DC, Herrington DM. Effect of genetic variations in platelet glycoproteins Ibalpha and VI on the risk for coronary heart disease events in postmenopausal women taking hormone therapy. Blood. 2007 Mar 01; 109(5):1862-9.
Score: 0.040
-
Abdelhamed AI, Reis SE, Sane DC, Brosnihan KB, Preli RB, Herrington DM. No effect of an L-arginine-enriched medical food (HeartBars) on endothelial function and platelet aggregation in subjects with hypercholesterolemia. Am Heart J. 2003 Mar; 145(3):E15.
Score: 0.031
-
Herrington DM, Klein KP. Randomized clinical trials of hormone replacement therapy for treatment or prevention of cardiovascular disease: a review of the findings. Atherosclerosis. 2003 Feb; 166(2):203-12.
Score: 0.031
-
Preli RB, Klein KP, Herrington DM. Vascular effects of dietary L-arginine supplementation. Atherosclerosis. 2002 May; 162(1):1-15.
Score: 0.029
-
Talbot D, Delaney JAC, Sandfort V, Herrington DM, McClelland RL. Importance of the lipid-related pathways in the association between statins, mortality, and cardiovascular disease risk: The Multi-Ethnic Study of Atherosclerosis. Pharmacoepidemiol Drug Saf. 2018 04; 27(4):365-372.
Score: 0.022
-
Qureshi WT, Michos ED, Flueckiger P, Blaha M, Sandfort V, Herrington DM, Burke G, Yeboah J. Impact of Replacing the Pooled Cohort Equation With Other Cardiovascular Disease Risk Scores on Atherosclerotic Cardiovascular Disease Risk Assessment (from the Multi-Ethnic Study of Atherosclerosis [MESA]). Am J Cardiol. 2016 09 01; 118(5):691-6.
Score: 0.019
-
Chotenimitkhun R, D'Agostino R, Lawrence JA, Hamilton CA, Jordan JH, Vasu S, Lash TL, Yeboah J, Herrington DM, Hundley WG. Chronic statin administration may attenuate early anthracycline-associated declines in left ventricular ejection function. Can J Cardiol. 2015 Mar; 31(3):302-7.
Score: 0.017
-
Kitzman DW, Brubaker PH, Herrington DM, Morgan TM, Stewart KP, Hundley WG, Abdelhamed A, Haykowsky MJ. Effect of endurance exercise training on endothelial function and arterial stiffness in older patients with heart failure and preserved ejection fraction: a randomized, controlled, single-blind trial. J Am Coll Cardiol. 2013 Aug 13; 62(7):584-92.
Score: 0.016
-
Polak JF, Pencina MJ, Herrington D, O'Leary DH. Associations of edge-detected and manual-traced common carotid intima-media thickness measurements with Framingham risk factors: the multi-ethnic study of atherosclerosis. Stroke. 2011 Jul; 42(7):1912-6.
Score: 0.014
-
Wenger NK, Lewis SJ, Herrington DM, Bittner V, Welty FK. Outcomes of using high- or low-dose atorvastatin in patients 65 years of age or older with stable coronary heart disease. Ann Intern Med. 2007 Jul 03; 147(1):1-9.
Score: 0.010
-
Mohler ER, Herrington D, Ouyang P, Mangano C, Ritter S, Davis P, Purkayastha D, Gatlin M, Vogel RA. A randomized, double-blind trial comparing the effects of amlodipine besylate/benazepril HCl vs amlodipine on endothelial function and blood pressure. J Clin Hypertens (Greenwich). 2006 Oct; 8(10):692-8.
Score: 0.010
-
Ouyang P, Tardif JC, Herrington DM, Stewart KJ, Thompson PD, Walsh MN, Bennett SK, Heldman AW, Tayback MA, Wang NY. Randomized trial of hormone therapy in women after coronary bypass surgery. Evidence of differential effect of hormone therapy on angiographic progression of disease in saphenous vein grafts and native coronary arteries. Atherosclerosis. 2006 Dec; 189(2):375-86.
Score: 0.009
-
Grady D, Herrington D, Bittner V, Blumenthal R, Davidson M, Hlatky M, Hsia J, Hulley S, Herd A, Khan S, Newby LK, Waters D, Vittinghoff E, Wenger N. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA. 2002 Jul 03; 288(1):49-57.
Score: 0.007
-
Furberg CD, Vittinghoff E, Davidson M, Herrington DM, Simon JA, Wenger NK, Hulley S. Subgroup interactions in the Heart and Estrogen/Progestin Replacement Study: lessons learned. Circulation. 2002 Feb 26; 105(8):917-22.
Score: 0.007